Torisel: Difference between revisions
m Protected "Torisel": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Temsirolimus''' is an intravenous drug for the treatment of [[renal cell carcinoma]] (RCC), developed by [[Wyeth]] Pharmaceuticals and approved by the [[FDA]] in late May 2007.<ref>[http://www.fda.gov/bbs/topics/NEWS/2007/NEW01644.html FDA.gov]</ref> It is a derivative of the [[macrolide]] [[sirolimus]]. | '''Temsirolimus''' is an intravenous drug for the treatment of [[renal cell carcinoma]] (RCC), developed by [[Wyeth]] Pharmaceuticals and approved by the [[FDA]] in late May 2007.<ref>[http://www.fda.gov/bbs/topics/NEWS/2007/NEW01644.html FDA.gov]</ref> It is a derivative of the [[macrolide]] [[sirolimus]]. | ||
| Line 34: | Line 34: | ||
[[Category:Macrolide antibiotics]] | [[Category:Macrolide antibiotics]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:59, 20 August 2012
| File:Temsirolimus.png | |
| Identifiers | |
|---|---|
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
|
WikiDoc Resources for Torisel |
|
Articles |
|---|
|
Most recent articles on Torisel |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Torisel at Clinical Trials.gov Clinical Trials on Torisel at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Torisel
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Torisel Risk calculators and risk factors for Torisel
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Torisel |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007.[1] It is a derivative of the macrolide sirolimus.
The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).[2] The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Macrolide antibiotics